The present study shows that ROCK inhibition targeted to PDGFRβ might be a promising strategy to treat PHT in cirrhosis without adverse extrahepatic hemodynamic effects. The gene discussed is PDGFRB; the disease is pulmonary hypertension, primary, 1.